Pharsight

Glaxosmithkline Llc patents expiration

1. Lamictal Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919115 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jan, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840925 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(4 years from now)

US9339504 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(4 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 08 May, 2009

Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of LAMICTAL ODT before it's drug patent expiration?
More Information on Dosage

LAMICTAL ODT family patents

Family Patents

2. Lamictal Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547 GLAXOSMITHKLINE LLC Oral dosage form for controlled drug release
Sep, 2023

(6 days ago)

US8637512 GLAXOSMITHKLINE LLC Formulations and method of treatment
Jun, 2028

(4 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 29 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LAMICTAL XR before it's drug patent expiration?
More Information on Dosage

LAMICTAL XR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic